Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

Wall Street researchers have made a groundbreaking leap in drug development by utilizing AI-powered tool Claude to design a new drug, showcasing the technology's potential to revolutionize medical research. This milestone not only validates long-standing claims about AI's transformative power but also sparks a new investment thesis around companies leveraging AI for groundbreaking medical advancements. Investors are now keenly eyeing firms that harness AI in drug development, suggesting a significant shift in the biotech sector's future.